Brazil Approves Medical Marijuana Rules, Blocks Cannabis Cultivation

巴西批准《医用大麻规则》,禁止大麻种植

2020-01-06 08:20:21 420 Magazine

本文共619个字,阅读需2分钟

RIO DE JANEIRO – Brazilian pharmaceutical regulator Anvisa on Tuesday approved regulations for the roll-out of medicinal cannabis-based products but in a separate vote blocked a proposal to allow domestic medical marijuana plantations. Anvisa’s approval of rules to regulate the nascent medical marijuana market represents a major shift in a country that has suffered years of deadly drug violence. Nonetheless, the decision to prohibit domestic plantations shows that Brazil, led by far-right President Jair Bolsonaro, is not yet willing to join peers Colombia and Uruguay and develop its own vertically integrated medical marijuana sector. A spokesman for Anvisa said that Brazilian firms interested in manufacturing cannabis-based products would need to import inputs from aboard. In its statement announcing the regulatory approval, Anvisa said the new rules would be published in the country’s official gazette in the next few days and come into law 90 days after that. Anvisa also set out specific rules for the manufacture, import, sale, packaging, marketing and regulation of the new class of cannabis-based products. Brazil’s decision to allow cannabis-based products is part of a slowly changing worldwide view toward illegal drugs, with growing investment in the medicinal benefits of marijuana and other narcotics. Nonetheless, in regional terms, Brazil may be arriving late, with both Uruguay and Colombia having both legalized medical marijuana and actively working toward gaining a firm foothold in the booming multibillion-dollar global market. Uruguay was the first country to legalize the growing, sale and smoking of marijuana in December 2013 in a pioneering social experiment closely watched by other nations debating drug liberalization. Colombia has also legalized medical marijuana, while in Mexico, the supreme court ordered the country’s health ministry to speed up its issuance of medical marijuana regulations, with recreational cannabis also being discussed by lawmakers. Anvisa said that cannabis-based products will only be available for sale in registered pharmacies, and with a prescription.
巴西药品监管机构安伟士( Anvisa )周二批准了推出药用大麻产品的法规,但在另一次投票中,否决了允许国内医用大麻种植的提案。 Anvisa 批准了监管新生医用大麻市场的规则,这标志着这个多年来遭受致命毒品暴力的国家发生了重大转变。 尽管如此,禁止国内种植的决定表明,以极右翼总统贾尔•博索尼罗( Jair Bolsonero )为首的巴西还不愿意加入哥伦比亚和乌拉圭的同行行列,发展自己垂直一体化的医用大麻部门。 Anvisa 的一位发言人说,有意生产基于大麻的产品的巴西公司需要从国外进口产品。 安伟士在宣布监管机构批准的声明中表示,新规定将在未来几天在中国官方公报上公布,并在90天后生效。Anvisa 还规定了生产、进口、销售、包装、营销和监管新型大麻产品的具体规则。 巴西决定允许以大麻为基础的产品,这是世界范围内对非法药物的观点逐渐改变的一部分,因为对大麻和其他毒品的药用利益的投资越来越多。 尽管如此,从地区来看,巴西可能会迟到,乌拉圭和哥伦比亚都已将医用大麻合法化,并积极努力在蓬勃发展的数十亿美元全球市场获得稳固的立足点。 2013年12月,乌拉圭是第一个将大麻的种植、销售和吸烟合法化的国家,这是在其他国家密切关注的一项开创性的社会实验中。 哥伦比亚还将医用大麻合法化,而在墨西哥,最高法院命令该国卫生部加快颁布医用大麻法规,立法者也在讨论娱乐大麻。 Anvisa 说,基于大麻的产品将只能在注册药店销售,并有处方。

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文